The Middle
East Tapentadol market, by Therapeutic Application (Pain Management
(Neuropathic Pain, Cancer Pain, and Others), and Cough Treatment), and by
Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) was valued at US$ 0.86
million in 2016 and is projected to exhibit a CAGR of 6.1% over the forecast
period (2017–2025).
Rising prevalence of
pain-associated diseases such as cancer and diabetic neuropathy and
unavailability of effective alternate therapy for management of neuropathic
pain are expected to be the major factors driving growth of the Middle East
tapentadol market over the forecast period. Janssen Pharmaceutical sold its
license of marketing and distribution of the U.S. to Depomed, Inc. and in April
2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical
trials for tapentadol are being carried on for various indications and age
groups.
Tapentadol is an opioid
analgesic, indicated for severe pain management, on a daily or around the clock
need for treatment and long-term opioid treatment, for which alternative
treatment options are inadequate. Tapentadol is also indicated for neuropathic
pain associated with diabetic peripheral neuropathy. It is widely used for
management of acute, chronic, and cancer related pain among patients and is
available legally on prescription. Nucynta ER is the first and only
FDA-approved long-acting opioid analgesic designed to control both, nociceptive
pain and neuropathic pain associated with diabetic peripheral neuropathy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1054
Nucynta is available as Palexia
outside the U.S. territory. Nucynta ER is contraindicated for patients
suffering from significant respiratory depression, known or suspected
gastrointestinal obstruction, acute or severe bronchial asthma or hypercarbia,
including paralytic ileus, concurrent use of monoamine oxidase inhibitors
(MAOIs), and Hypersensitivity (e.g. anaphylaxis, angioedema) to tapentadol or
to any other ingredients of the product or use of MAOIs within a period of 14
days.
Positive results from these
trials is expected to cause the tapentadol market to gain rapid traction.
Currently, tapentadol is only approved for consumption by adults and is not
recommended for children due to its high therapeutic efficacy. However, one in
three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label
trial, enrolling subjects aged 6 years to 18 years, which is estimated to be
completed in December 2018. Another trial by St. Olavs Hospital is for pre- and
post-operative pain relief after primary knee arthroplasty with estimated study
completion year 2021.
Browse 10 Market Data Tables And
11 Figures Spread Through 106 Pages and In-depth TOC on Middle East Tapentadol
Market, By Therapeutic Application (Pain Management (Neuropathic Pain, Cancer
Pain, And Others), And Cough Treatment), and By Countries (KSA, UAE, Bahrain,
Oman, Qatar, Israel, Iran) - Forecast To 2025.
Tapentadol can be used for
various other applications, as it is also found to be the safest and best
first-line treatment choice for advanced chronic kidney disease. However, clinical
trials are still required for it to be prescribed for the same. Furthermore,
pilot studies have been performed on patients suffering from moderate-to-severe
chronic back pain, published in the National Center for Biotechnology
Information. Increasing off-label applications for this moderately addictive
drug along with low competition for existing indications, and robust pipeline
is expected to boost growth of the tapentadol market over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/tapentadol-market-1054
Key Takeaways of the Middle East
Tapentadol Market:
The Middle East tapentadol market
is expected to exhibit a CAGR of 1% over the forecast period (2017–2025), owing
to the high prevalence of pain-related diseases in countries such as Iran,
Palestine, and Kingdom of Saudi Arabia. For instance, according to Journal of
Taibah University Medical Sciences, the prevalence of diabetic neuropathic pain
in Iran was 51.90% in 2016.
Positive results of clinical
trials of tapentadol are expected to drive growth of the tapentadol market
further
Absence of generic drugs after
patent win by Depomed, Inc. in 2016, has abolished the competition
Less likelihood of tough
competition from any other opioid for neuropathic pain and absence of any other
opioid therapy under research is expected to support growth of the market
Some major players operating in
the tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc.,
Grünenthal, and Allergan, Plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1054
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment